Shire to acquire Baxalta in $32 billion deal
Shire plc plans to buy Baxalta Inc., a biopharmaceutical company focused on orphan diseases and underserved conditions, in a cash and stock deal valued at $32 billion. Under the agreement, Baxalta shareholders will receive $18 in cash and 0.